Dr. Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centred on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies. Her research has helped establish the role of intravenous immunoglobulin in the treatment of myasthenia gravis and the Guillain-Barr Syndrome, and the long-term treatment of chronic inflammatory demyelinating polyneuropathy. She has acted in an advisory capacity to Health Canada and the FDA.
Dr. Bril also serves as the Deputy Physician-in-Chief for Economic Affairs for the Department of Medicine at University Health Network and Mount Sinai Hospital and Chair of the Economics committee. She is part of the Department of Medicine Executive Committee and helps administer this group of 300 physicians.
Industry Expertise (6)
Health Care - Services
Health Care - Providers
Health Care - Facilities
Health and Wellness
Areas of Expertise (10)
Diabetic Sensorimotor Polyneuropathy
Neural and Sensory Sciences
Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
- University of Toronto : Professor, Department of Medicine (Neurology)
- University Health Network and Mount Sinai Hospital: Head, Division of Neurology
- Neuromuscular Program: Director
- Krembil Family Chair in Neurology
- University Health Network and Mount Sinai Hospital: Deputy Physician-in-Chief, Economic Affairs, Department of Medicine
- Economics committee: Chair
Media Appearances (3)
Dr Vera Bril places “first-in-class” in Canadian Diabetes Association research granting competition
The Brain Campaign online
The Competition for peer reviewed research funding is fierce. Countless researchers around the country, and in some cases, the world, work for months preparing grant funding requests; defend their applications before committees made up of national and international experts and people living the respective disease; and answer detailed questions about their submission to receive scarce funding for their research projects...
Dr. M. Barbara Berner establishes Fellowship
UHN General & Western Hospital Foundation online
Treated by Dr. Vera Bril, leader of the Neuromuscular Clinic at UHN, ever since, Dr. Berner recently expressed her gratitude profoundly. By funding both a fellowship in neuromuscular research – as well as confirming an annual gift to support the current fellowship, and leaving a more significant gift in her Will to support the fellowship in perpetuity – Dr. Berner's support promises to make a sizable difference in MG treatments, both now and into the future...
American Academy of Neurology online
This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns with Dr. Paola Sandroni about her paper on orthostatic intolerance. Dr. Jennifer Fugate is reading our e-Pearl of the week about bright tongue sign. In the next part of the podcast Dr. Ted Burns interviews Dr. Vera Bril about symptomatic treatment of painful diabetic neuropathy...
Event Appearances (1)
Diagnosis and Management of CIDP
CBS/CIDP Douncation of Canada, National Conference Toronto, ON.
The basic question asked was: “What is the efficacy of a given treatment (pharmacological: anticonvulsants, antidepressants, opioids, others; and non-pharmacological: electrical stimulation, magnetic field treatment, low-intensity laser treatment, Reiki massage, others) to reduce pain and improve physical function and quality of life (QOL) in patients with PDN?”
Short-term studies suggest that intravenous immunoglobulin might reduce disability caused by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not been shown. We aimed to establish whether 10% caprylate- ...
The diabetic neuropathies are hetero-geneous, affecting different parts of the nervous system that present with diverse clinical manifestations. They may be focal or diffuse. Most common among the neuropathies are chronic sensorimotor distal symmetric ...
The utility of rapid and reliable sensory tests appropriate for the diagnosis of neuropathy in the diabetes clinic, rather than as prognostic tools for the prediction of foot complications, has been unclear because of limitations inherent in previous studies. ...
There is reason to believe that diabetic neuropathy may be related to the accumulation of sorbitol in nerve tissue through an aldose reductase pathway from glucose. Short-term treatment with aldose reductase inhibitors improves nerve conduction in ...
Altered sorbitol and myo-inositol metabolism,(Na, K)-ATPase function, electrochemical sodium gradients, axonal swelling, and distortion and disruption of the node of Ranvier (" axo-glial dysjunction") directly implicate hyperglycemia in the pathogenesis ...